Blunted Refeeding Response and Increased Locomotor Activity in Mice Lacking FoxO1 in Synapsin-Cre–Expressing Neurons
- Hongxia Ren1,2,
- Leona Plum-Morschel1,2,
- Roger Gutierrez-Juarez3,
- Taylor Y. Lu1,2,
- Ja Young Kim-Muller1,2,
- Garrett Heinrich1,2,
- Sharon L. Wardlaw1,2,
- Rae Silver4 and
- Domenico Accili1,2⇑
- 1Berrie Diabetes Center, New York, New York
- 2Department of Medicine, Columbia University, New York, New York
- 3Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, New York
- 4Department of Psychology, Columbia University, New York, New York.
- Corresponding author: Domenico Accili, .
H.R. and L.P.-M. contributed equally to this work.
Successful development of antiobesity agents requires detailed knowledge of neural pathways controlling body weight, eating behavior, and peripheral metabolism. Genetic ablation of FoxO1 in selected hypothalamic neurons decreases food intake, increases energy expenditure, and improves glucose homeostasis, highlighting the role of this gene in insulin and leptin signaling. However, little is known about potential effects of FoxO1 in other neurons. To address this question, we executed a broad-based neuronal ablation of FoxO1 using Synapsin promoter–driven Cre to delete floxed Foxo1 alleles. Lineage-tracing experiments showed that NPY/AgRP and POMC neurons were minimally affected by the knockout. Nonetheless, Syn-Cre-Foxo1 knockouts demonstrated a catabolic energy homeostatic phenotype with a blunted refeeding response, increased sensitivity to leptin and amino acid signaling, and increased locomotor activity, likely attributable to increased melanocortinergic tone. We confirmed these data in mice lacking the three Foxo genes. The effects on locomotor activity could be reversed by direct delivery of constitutively active FoxO1 to the mediobasal hypothalamus, but not to the suprachiasmatic nucleus. The data reveal that the integrative function of FoxO1 extends beyond the arcuate nucleus, suggesting that central nervous system inhibition of FoxO1 function can be leveraged to promote hormone sensitivity and prevent a positive energy balance.
- Received April 15, 2013.
- Accepted June 20, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.